Nerivio®, a drug-free migraine treatment, now available in Germany thanks to Dr. Reddy’s subsidiary betapharm and Theranica’s partnership

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY), a global pharmaceutical company, announced the launch of Nerivio® Remote Electrical Neuromodulation (REN) wearable through its subsidiary betapharm. The launch in Germany marks Dr. Reddy’s entry into digital therapeutics in Europe. Nerivio® is a United States Food and Drug Administration (USFDA) and CE-marked…

Source